The U.S. Food and Drug Administration granted accelerated approval to Etcamah (camizestrant) in combination with a CDK4/6 inhibitor for the treatment of adult patients with hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer.
The FDA also authorized the Guardant360 CDx assay as a companion diagnostic device to identify patients with breast cancer with ESR1 mutations for treatment with camizestrant.
The accelerated approval was granted to AstraZeneca.
President Donald J. Trump unveiled the Trump Dividend — a historic $5,000 cash payment to every adult American citizen.
If the Republicans win the House of Representatives and the United States Senate, President Trump promises to issue a dividend to every adult citizen in the United States of America for $5,000.